GASTRIC CANCER

This study tests a new treatment approach for people with advanced stomach or gastroesophageal junction cancer that has spread. Participants first receive targeted radiation and a drug called olaparib, followed by a combination of olaparib and pembrolizumab. The goal is to see if…

This early-stage trial tests several new drug combinations in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if these combinations can shrink tumors or slow their growth. About 352 participants with cancers…

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This study looks at whether using just one or a few small cuts (single or reduced ports) for laparoscopic stomach cancer surgery is safe and works well. It involves 108 people with advanced stomach cancer. The main goal is to see how many lymph nodes can be removed, and the study…

This study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the …

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This study tests a drug called AZD0901 in 33 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The cancer must have a specific protein (Claudin18.2). The goal is to see if the drug can shrink tumors and how safe it is. Pa…

This study compares a new esophageal stent (Luso-Cor) with standard stents and vacuum therapy for closing leaks that can happen after weight-loss or cancer surgery on the stomach or esophagus. About 180 adults who develop these leaks will be enrolled. The goal is to see which met…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy and trastuzumab can improve outcomes for people with HER2-positive stomach or gastroesophageal junction cancer that can be surgically removed. About 42 participants will receive treatment…

This study tests whether a combination of three drugs (fruquintinib, sintilimab, and SOX chemotherapy) can shrink advanced stomach cancer enough to allow surgical removal. About 42 adults with stage IV gastric cancer that has spread to nearby organs or lymph nodes will receive th…

This study tests a new drug combination for people with advanced stomach cancer that has spread. It includes an antibody-drug conjugate (RC48-ADC) plus immunotherapy (toripalimab) and either chemotherapy or another targeted drug (trastuzumab). The goal is to see if these combos c…

This study tests a drug called zolbetuximab for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). The drug works by attaching to that protein and helping the immune system attack the tumor. Participants receive zolbetuximab a…

This early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors like lung, bladder, or ovarian cancer. The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be …

This early-stage study tests a new drug called TORL-2-307-ADC in people with advanced solid tumors, including stomach, pancreas, and esophageal cancers. The main goals are to find a safe dose and check for side effects. About 163 participants will receive the drug to see if it ca…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) that have stopped responding to standard immunotherapy drugs called PD-1/PD-L1 inhibitors. Researchers are testing a new combination of immune-boosting drugs to see if they can shrink tumors …

This study tests an experimental drug called IDX-1197 combined with standard chemotherapy (XELOX or irinotecan) in 87 people with advanced stomach cancer that has spread or come back. The main goals are to find the safest dose and see if the combination helps control the cancer. …

This study tests a combination of two drugs—vorbipiprant and balstilimab—in people with advanced colorectal or other gastrointestinal cancers that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About…

This early-phase trial tests whether giving immunotherapy drugs (nivolumab or nivolumab/relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. The goal is to see if this approach can ch…

This study tests whether adding an experimental drug (ONO-4578) to standard chemotherapy and immunotherapy can help people with advanced stomach cancer live longer without their cancer growing. About 226 adults who have not had chemotherapy before are taking part. The goal is to …

This study tests a new drug called ASKB589 combined with standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps control the cancer. The…

This study compares 4 months versus 6 months of chemotherapy (capecitabine and oxaliplatin) in 1024 stomach cancer patients who had surgery. The goal is to see if the shorter treatment works just as well to prevent cancer from coming back, while causing fewer side effects. Partic…

This study tests a new drug called Q702 combined with pembrolizumab (an immunotherapy) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and shrinks tumors. About 120 parti…

This study tests an experimental drug called MCLA-129 in people with advanced non-small cell lung cancer and other solid tumors that have stopped responding to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c-MET) at…

This study tests a new drug called bemarituzumab combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be cured by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 72 adults will…

This study tests a new drug called RNDO-564, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like lung, bladder, or breast cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if t…

This study tests whether adding the drug bemarituzumab to standard chemotherapy and immunotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 515 adults whose tumors have a specific protein called FGFR2b. The goal i…

This study tests a new drug called TST001, an antibody that targets a protein (CLDN18.2) found on some cancer cells. It is for people with advanced solid tumors, including stomach, gastroesophageal junction, and pancreatic cancers. The trial aims to find safe doses and see how we…

This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The goal is to find a safe dose and see how well people tolerate it. About 72 participants will take…

This study tests a treatment for stomach cancer that has spread to the lining of the abdomen. It combines standard chemotherapy given through a vein with chemotherapy delivered directly into the belly. The goal is to see if this approach helps control the cancer and improves surv…

This early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a pro…

This early-phase trial tests a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes adults with advanced stomach, es…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma). The therapy takes a patient's own immune cells and genetically equips them to recognize and attack tumors that …

This early-stage study tests a new experimental drug (RO7496353) combined with an immunotherapy drug, with or without standard chemotherapy, in people with advanced lung, stomach, or pancreatic cancer. The main goal is to check safety and find the right dose. About 102 participan…

This study tests whether giving a combination of three drugs (lenvatinib, pembrolizumab, and FLOT chemotherapy) before and after surgery can help shrink or eliminate stomach cancer in 43 adults. Participants have early-stage stomach cancer that has not spread. The main goal is to…

This study is testing an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, pancreatic, and prostate cancer. The goal is to see if the drug is safe and tolerable when given alone or with other cancer treatments. About 70…

This study tests a new experimental drug, HFB200603, either alone or combined with another cancer drug (tislelizumab), in adults with advanced solid tumors like kidney, lung, skin, stomach, or colorectal cancer. The goal is to find safe doses and understand side effects. About 83…

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that has spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…

This study tests whether adding the drug bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 547 adults whose tumors have high levels of a protein called FGFR2b. Participants receive e…

This study tests a new magnetic dye and detector to find cancer that has spread to nearby lymph nodes in people with stomach or esophagus cancer. About 60 adults who are scheduled for surgery will receive the dye, and doctors will check how well it works compared to standard meth…

This study looks at whether a special type of CT scan (spectral CT) combined with a genetic test (MSI) can better predict if stomach cancer has spread to nearby lymph nodes. Researchers will compare the scan results with the actual lymph node status found during surgery. The goal…

This study screens people for H. pylori, a stomach infection that can lead to chronic inflammation, ulcers, and even stomach cancer. Those who test positive receive treatment to wipe out the bacteria. The goal is to prevent these serious stomach problems. About 75 participants fr…

This study screens 500 adults in South Florida for H. pylori, a stomach infection that can lead to chronic inflammation, ulcers, and even stomach cancer. People who test positive get free treatment right away. The goal is to catch and treat the infection early to prevent serious …

This study tests whether personalized screening—using stool tests, blood tests, and risk scores—can better prevent stomach and colon cancer in adults aged 50-75. Researchers will enroll 40,000 healthy participants and track them over time. The goal is to find the most effective w…

This study tests whether using a FitBit and mobile health apps can help people who have had surgery for cancers of the stomach, liver, pancreas, colon, or small intestine avoid being readmitted to the hospital. About 107 adults who own a smartphone and are scheduled for surgery w…

This study tests a special pouch made from the small intestine to help people who have had their entire stomach removed due to cancer. The goal is to reduce dumping syndrome—a common problem causing nausea, sweating, and diarrhea after eating—and improve nutrition and quality of …

This study looks at people with advanced stomach cancer that is causing a blockage. It compares two types of surgery: removing the blocked part of the stomach or creating a bypass around it. The goal is to see which surgery better relieves symptoms like nausea and vomiting. The s…

This study looks at whether a diet low in leucine (an amino acid) is safe for people with stomach cancer. About 37 patients will follow this special diet before surgery. Researchers will check blood levels of amino acids, immune cell changes, and any side effects.

This study explores whether a special type of radiation therapy can protect the ovaries of young women (ages 18-50) undergoing pelvic radiation for cancers like uterine, rectal, or cervical cancer. The goal is to see if doctors can consistently see the ovaries on daily scans and …

This study collects leftover tissue, blood, and other body fluids from up to 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in future lab studies to learn more about what causes these cancers…

This study reviews medical records from 230 adults across 15 hospitals in 2 countries to understand how brain metastases from stomach and esophageal cancers are treated. The goal is to see which local treatments (like surgery or radiation) work best and how long patients live aft…